Natera: president Fesko sells $239k in shares

Published 31/07/2025, 03:00
Natera: president Fesko sells $239k in shares

John Fesko, President and Chief Business Officer at Natera, Inc. (NASDAQ:NTRA), sold 1,710 shares of common stock on July 28, 2025, at a price of $139.8083, for a total value of $239,072. The transaction occurred in a $19.2 billion market cap company that, according to InvestingPro analysis, is currently trading above its Fair Value.

Following the transaction, Fesko directly owns 151,750 shares of Natera.

The sale was executed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) under a pre-arranged 10b5-1 trading plan.

In other recent news, Natera has reported a series of significant developments. The company showcased strong performance in the first quarter of 2025, prompting RBC Capital Markets to maintain their Outperform rating and a price target of $251. This confidence is supported by Natera’s accelerated revenue growth and increased financial guidance. Additionally, Medicare has expanded its coverage for Natera’s Signatera MRD assay to include a broader range of cancers, following a study presented at the American Society of Clinical Oncology Annual Meeting. This expansion is expected to enhance the company’s market reach.

Analysts at TD Cowen have also raised their price target for Natera to $200, citing a 13% sales increase, driven by a 5% rise in core sales and other favorable factors. The company’s Signatera product has shown remarkable growth, with clinical volumes rising to approximately 17,000 in the first quarter, a 52% year-over-year increase. Evercore ISI initiated coverage with an Outperform rating and a $170 price target, suggesting potential upside. Meanwhile, Leerink Partners reiterated their Outperform rating, maintaining a $220 price target, following Medicare’s coverage decision for Natera’s WGS Signatera assay. These developments reflect a positive outlook from multiple analyst firms on Natera’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.